aTyr Pharma Q1 2024 update: Phase 3 EFZO-FIT completes enrollment expected in Q2 2024

aTYR PHARMA INC

Cash, cash equivalents, restricted cash and investments totaled $87.7 million as of March 31, 2024.
Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis enrollment completion expected in Q2 2024.
Phase 2 EFZO-CONNECT study in systemic sclerosis-associated ILD enrolling at multiple U.S. sites.
R&D expenses of $13.4 million and G&A expenses of $3.5 million for Q1 2024.
Collaboration revenue of $0.2 million from Kyorin agreement for drug product material sold.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

aTYR PHARMA INC reported financial results for the three months ended March 31, 2024.

Period: the three months ended March 31, 2024
Result: reported results

Exact text from the filing

On May 2, 2024, aTyr Pharma, Inc. issued a press release announcing financial results for the three months ended March 31, 2024.

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

aTYR PHARMA INC filing history →

Source: SEC EDGAR

accession 0000950170-24-052058

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.